Ibrutinib and Venetoclax for First-Line Treatment of CLLNitin Jain, William G. Wierda, Prithviraj Bose et al.|New England Journal of Medicine|2019Cited by 502
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trialsTimothy A. Yap, Marina Konopleva, Naval Daver et al.|Nature Medicine|2023Cited by 372
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trialCourtney D. DiNardo, Marina Konopleva, Abhishek Maiti et al.|The Lancet Haematology|2020Cited by 330
Outcomes of <i>TP53</i>‐mutant acute myeloid leukemia with decitabine and venetoclaxKunhwa Kim, Marina Konopleva, Abhishek Maiti et al.|Cancer|2021Cited by 156
Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 InhibitorsAhmad S. Alotaibi, Naval Daver, Musa Yılmaz et al.|Blood Cancer Discovery|2020Cited by 97